Vanda Pharmaceuticals
VNDA
133 hedge funds and large institutions have $633M invested in Vanda Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 53 increasing their positions, 46 reducing their positions, and 15 closing their positions.
281% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $497K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
15% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 46
14% more capital invested
Capital invested by funds: $556M → $633M (+$77.2M)
2% less funds holding
Funds holding: 136 → 133 (-3)
3.12% less ownership
Funds ownership: 90.34% → 87.22% (-3.1%)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$13.2M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$9.25M |
| 3 |
BlackRock
New York
|
+$8.86M |
| 4 |
AC
Armistice Capital
New York
|
+$6.57M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$32.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.81M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.8M |
| 4 |
Morgan Stanley
New York
|
-$5.91M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$4.04M |
VNDA Hedge Fund Activity: Q2 2017 in Review
133 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2017, worth a combined $633M — up 14% from $556M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of VNDA and 13 opened new positions — a net loss of 2 holders — while 46 trimmed existing stakes and 53 added.
The largest buyer was OrbiMed, adding an estimated $13.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $32.2M sold.
- 133 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2017, down from 136 in Q1 2017.
- Funds reported $633M of Vanda Pharmaceuticals stock for Q2 2017, up 14% quarter-over-quarter.
- 13 funds opened new Vanda Pharmaceuticals positions in Q2 2017 and 15 closed out, a net change of -2 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2017 was OrbiMed, an estimated $13.2M added.
- The largest Vanda Pharmaceuticals seller in Q2 2017 was Deerfield Management, an estimated $32.2M sold.
Based on aggregated 13F filings for Q2 2017.